文献速递肝病消化道肿瘤与早癌

TAZ对c-MYC诱导的肝癌发生不可或缺

TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
PubMed 文献 · J Hepatol · 2021-08-28

研究利用条件性基因敲除小鼠模型,探究YAP/TAZ在c-MYC驱动肝细胞癌(HCC)中的作用。发现Hippo通路在c-Myc诱导的小鼠HCC中失活,TAZ是c-MYC的直接转录靶点,敲除Taz而非Yap可完全阻止肿瘤发生并促使已形成肿瘤消退。靶向TAZ可能对c-MYC激活的HCC患者有益。

要点

  • TAZ是c-MYC的直接转录靶点,其mRNA和激活状态与c-MYC活性相关。
  • 在c-Myc小鼠HCC中,敲除Taz而非Yap可完全预防肿瘤发生。
  • TAZ通过避免c-Myc诱导的肝细胞凋亡及调控BCL2L12促进肿瘤起始和进展。

核心结论

  • TAZ是连接c-MYC和Hippo通路的关键分子,靶向TAZ可能有益于c-MYC激活的HCC患者治疗。

研究设计与样本

  • 使用条件性Yap、Taz及Yap;Taz敲除小鼠分析c-Myc驱动肝癌发生中对YAP/TAZ的需求。
  • 应用肝细胞特异性可诱导TTR-CreERT2敲除系统评估YAP和TAZ在肿瘤进展中的作用。
  • 分析人HCC样本中YAP、TAZ、c-MYC和BCL2L12的表达模式。

主要发现

  • Hippo级联在c-Myc诱导的小鼠HCC中失活。
  • TAZ mRNA水平和激活状态与人及小鼠HCC中的c-MYC活性相关,而YAP mRNA水平不相关。
  • 在c-Myc诱导的小鼠HCC中,敲除Taz而非Yap完全阻止肿瘤发生。
  • TAZ在肿瘤起始阶段是避免c-Myc诱导肝细胞凋亡所必需的。
  • BCL2L12被鉴定为YAP/TAZ特异性调控的新靶点,其沉默强烈抑制c-Myc驱动的小鼠肝癌发生。

关键数值与推荐

  • TAZ是c-MYC的直接转录靶点。
  • BCL2L12基因受YAP/TAZ特异性调控。

临床怎么用

  • TAZ可作为c-MYC驱动HCC的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development. METHODS: The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreERT2 KO system was applied to evaluate the role of YAP and TAZ during tumor progression. Expression patterns of YAP, TAZ, c-MYC, and BCL2L12 were analyzed in human HCC samples. RESULTS: We found that the Hippo cascade is inactivated in c-Myc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In c-Myc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression. CONCLUSIONS: TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and c-MYC activation. LAY SUMMARY: The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang H, Zhang S, Zhang Y, et al. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. J Hepatol. 2021. PMID: 34464659. doi:10.1016/j.jhep.2021.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。